56 results
424B5
XENE
Xenon Pharmaceuticals Inc
30 Nov 23
Prospectus supplement for primary offering
4:18pm
and state anti-kickback, fraud and abuse, false claims, transparency, health information privacy and security, and other healthcare laws … obtain marketing approval. In addition, we may be subject to transparency laws and patient privacy regulation by the federal government and by the U.S
424B5
XENE
Xenon Pharmaceuticals Inc
29 Nov 23
Prospectus supplement for primary offering
5:05pm
will be subject, directly or indirectly, to applicable federal and state anti-kickback, fraud and abuse, false claims, transparency, health information privacy … market, sell and distribute any products for which we obtain marketing approval. In addition, we may be subject to transparency laws and patient privacy
424B5
wk8 8snx8gs
23 Jun 22
Prospectus supplement for primary offering
4:09pm
424B5
6xua3o c1
22 Jun 22
Prospectus supplement for primary offering
4:05pm
424B5
nb8h3d
1 Mar 22
Prospectus supplement for primary offering
5:12pm
424B5
ks209e
6 Oct 21
Prospectus supplement for primary offering
5:05pm
424B5
mzhkvj8h
4 Oct 21
Prospectus supplement for primary offering
5:27pm
424B5
hoi6ansd
9 Mar 21
Prospectus supplement for primary offering
5:26pm